<!DOCTYPE html>
<html lang="en-us">
  <head>
	<meta name="generator" content="Hugo 0.85.0" />
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>fallingstar-Daily-rss | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>fallingstar-Daily-rss</span>
        <span>2024-06-04</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831569/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Spatial prioritization for widespread invasive species control: Trade-offs between current impact and future spread</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831569-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Spatially explicit prioritization of invasive species control is a complex issue, requiring consideration of trade-offs between immediate and future benefits. This study aimed to prioritize management efforts to account for current and future threats from widespread invasions and examine the strength of the trade-off between these different management goals. As a case study, we identified spatially explicit management priorities for the widespread invasion of introduced willow into riparian &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831719/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Disturbance in cerebral blood microcirculation and hypoxic-ischemic microenvironment are associated with the development of brain metastasis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831719-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Brain metastases (BM) constitute an increasing challenge in oncology due to their impact on neurological function, limited treatment options, and poor prognosis. BM occur through extravasation of circulating tumor cells across the blood-brain barrier. However, the extravasation processes are still poorly understood. We here propose a brain colonization process which mimics infarction-like microenvironmental reactions, that is dependent on Angiopoietin (Ang-2) and vascular endothelial &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831749/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">A Hypoxia-Epigenetics Axis Drives EMT in Pancreatic Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831749-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Epithelial-to-mesenchymal transition (EMT) is a classical cellular plasticity process induced by various cell-intrinsic and -extrinsic triggers. Although prominent factors, such as TGFÎ², mediate EMT via well-characterized pathways, alternative avenues are less well understood. Transcriptomic subtyping of pancreatic ductal adenocarcinoma (PDAC) has demonstrated that basal-like PDACs enrich a mesenchymal-like expression program, emphasizing the relevance of EMT in the disease. In this issue &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831754/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831754-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: A global consensus protocol has been developed for treatment planning for MR-guided pancreatic SBRT on a 1.5 T MR-Linac. Aside from harmonizing the large variation in the current clinical practice, this protocol can provide a starting point for centers that are planning to treat pancreatic tumors on MR-Linac &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831799/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Input precision, output excellence: the importance of dataÂ quality control and method selection in disease risk mapping -authors&#39; reply</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831799-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831935/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Expertise in surgical neuro-oncology. Results of a survey by the EANS neuro-oncology section</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831935-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Technical advances and the increasing role of interdisciplinary decision-making may warrant formal definitions of expertise in surgical &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831996/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">The Radiation Therapist profession through the lens of new technology: A practice development paper based on the ESTRO Radiation Therapist Workshops</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831996-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Technological advances in radiation therapy impact on the role and scope of practice of the radiation therapist. The European Society of Radiotherapy and Oncology (ESTRO) recently held two workshops on this topic and this position paper reflects the outcome of this workshop, which included radiation therapists from all global regions. Workflows, quality assurance, research, IGRT and ART as well as clinical decision making are the areas of radiation therapist practice that will be &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38832018/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Molecular maps of synovial cells in inflammatory arthritis using an optimized synovial tissue dissociation protocol</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38832018-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    In this study, we optimized the dissociation of synovial tissue biopsies for single-cell omics studies and created a single-cell atlas of human synovium in inflammatory arthritis. The optimized protocol allowed consistent isolation of highly viable cells from tiny fresh synovial biopsies, minimizing the synovial biopsy drop-out rate. The synovium scRNA-seq atlas contained over 100,000 unsorted synovial cells from 25 synovial tissues affected by inflammatory arthritis, including 16 structural, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38832418/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38832418-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38832863/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Transcranial transmission ultrasound for reliable non-invasive exclusion of intracranial hypertension in traumatic brain injury patients -A proof of concept study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38832863-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    For many years, non-invasive methods to measure intracranial pressure (ICP) have been unsuccessful. However, such methods are crucial for the assessment of patients with non-penetrating traumatic brain injuries (TBI) who are unconscious. In this study, we explored the use of Transcranial Transmission Ultrasound (TTUS) to gather experimental data through brain pulsatility, assessing its effectiveness in detecting high ICP using machine learning analysis. We included patients with severe TBI &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38832972/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38832972-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation. (Funded by Sanofi and a Cancer Center Support Grant; IMROZ ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38832972/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240604181823&amp;v=2.18.0.post9&#43;e462414">Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38832972-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240604181823-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation. (Funded by Sanofi and a Cancer Center Support Grant; IMROZ ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38832994/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Side effects of oncologic therapies</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38832994-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38833159/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Scientific methods for in-vitro investigations in the field of joint kinematics : Cluster experimental joint kinematics</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38833159-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    In vitro studies are an established method to determine joint kinematics for answering preclinical questions regarding the effects of new treatment options, surgical techniques or implant designs. The lack of standardized, interdisciplinary representation in the determination of joint kinematics poses a problem. In addition to representation forms such as the &ldquo;neutral-zero method&rdquo; or the description of movements within the three basic planes, there are other mathematical &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38833160/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Tribology in arthroplasty : Friction and wear, aÂ key to aÂ long lifetime</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38833160-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    This article is intended to highlight one of the key roles in endoprosthetic treatment with artificial implants and the extension of service life. Like every joint, artificial joints are subject to the physical laws of friction and wear-in short, tribology. Material pairings, surfaces and mechanisms of action in particular play a decisive role here. The special features and current findings relating to the three largest synovial joints (hip, knee and shoulder) will be discussed in detail &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/Ohre7BQ0M">æˆ‘ä»5:30ä¸‹ç­ï¼Œåˆ°ç°åœ¨å¿«12:30äº†ï¼Œä¸€ç›´ååœ¨ç”µè„‘å‰ï¼Œçœ‹å†…ç½‘çš„å„ç§ä¸“ä¸šèµ„æ–™å’Œå­¦ä¹ å¹³å°ï¼Œä¸æƒ³å»åƒé¥­æˆ–ç¡è§‰ï¼Œä¸€ç›´åœ¨è¯»èµ„æ–™ã€‚è¿™ç®—æ˜¯åœ¨æ»¡è¶³æˆ‘åŠè¾ˆå­å¯¹HIVçš„å¥½å¥‡å¿ƒã€‚</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-ohre7bq0m/">
    
    
    
    
    
      
    
    æˆ‘ä»5:30ä¸‹ç­ï¼Œåˆ°ç°åœ¨å¿«12:30äº†ï¼Œä¸€ç›´ååœ¨ç”µè„‘å‰ï¼Œçœ‹å†…ç½‘çš„å„ç§ä¸“ä¸šèµ„æ–™å’Œå­¦ä¹ å¹³å°ï¼Œä¸æƒ³å»åƒé¥­æˆ–ç¡è§‰ï¼Œä¸€ç›´åœ¨è¯»èµ„æ–™ã€‚è¿™ç®—æ˜¯åœ¨æ»¡è¶³æˆ‘åŠè¾ˆå­å¯¹HIVçš„å¥½å¥‡å¿ƒã€‚  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OhwHufkD4">ä»Šæ—©NIHå®£å¸ƒå°†å¯åŠ¨æ¯åŠå¹´æ³¨å°„ä¸€æ¬¡Gileadå¼€å‘çš„å·²ä¸Šå¸‚è¯ç‰©Lenacapavirç”¨äºHIVé¢„é˜²PrEPä¸´åºŠè¯•éªŒï¼Œä¸å£æœPrEPè¿›è¡Œå¯¹æ¯”ã€‚è¯¥ä¸´åºŠè¯•éªŒå°†ç”±HPTNå¼€å±•ï¼ˆNCT06101329å’ŒNCT0...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-ohwhufkd4/">
    
    
    
    
    
      
    
    ä»Šæ—©NIHå®£å¸ƒå°†å¯åŠ¨æ¯åŠå¹´æ³¨å°„ä¸€æ¬¡Gileadå¼€å‘çš„å·²ä¸Šå¸‚è¯ç‰©Lenacapavirç”¨äºHIVé¢„é˜²PrEPä¸´åºŠè¯•éªŒï¼Œä¸å£æœPrEPè¿›è¡Œå¯¹æ¯”ã€‚è¯¥ä¸´åºŠè¯•éªŒå°†ç”±HPTNå¼€å±•ï¼ˆNCT06101329å’ŒNCT06101342ï¼‰ã€‚STATç­‰åª’ä½“è¿›è¡Œäº†æŠ¥é“ã€‚å¦‚æœé•¿æ•ˆLenacapavirä¸é€Šäºæ—¥æœPrEPï¼Œé‚£ä¹ˆå…¶ä½¿ç”¨æ–¹å¼å°†æ¥è¿‘äºç–«è‹—ï¼Œä½†ä¿æŠ¤åŠ›è¿œé«˜äºç–«è‹—ã€‚æœŸå¾…å¥½æ¶ˆæ¯ã€‚  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhubAg2Ck">ğŸ”»ç¬‘æ­»#æ¸…ååšå£«é€æ°´æ³¥æˆ’æŒ‡æ±‚å©šè¢«å˜²ç¬‘# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohubag2ck/">
    
    
    
    
    
      
    
    ğŸ”»ç¬‘æ­»<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#æ¸…ååšå£«é€æ°´æ³¥æˆ’æŒ‡æ±‚å©šè¢«å˜²ç¬‘#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhujOpZZr">ğŸ”»â€œè¯¥è§†é¢‘åŒæ—¶æœ‰9ä¸ªäººæ­£åœ¨è§‚çœ‹â€æ˜¯æ€ä¹ˆå›äº‹ï¼ŸğŸ”»[å“†å•¦Aæ¢¦å®³æ€•] [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohujopzzr/">
    
    
    
    
    
      
    
    ğŸ”»â€œè¯¥è§†é¢‘åŒæ—¶æœ‰9ä¸ªäººæ­£åœ¨è§‚çœ‹â€æ˜¯æ€ä¹ˆå›äº‹ï¼Ÿ<!-- raw HTML omitted -->ğŸ”»<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/639b1bfbgy1hqdq7b5yv6j20zu1nvk4x.jpg%22">https://tvax1.sinaimg.cn/large/639b1bfbgy1hqdq7b5yv6j20zu1nvk4x.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ohuq2bYZo">ğŸ”»5 æœˆä»½ï¼Œè´¢æ–°åˆ¶é€ ä¸šé‡‡è´­ç»ç†äººæŒ‡æ•°ä»ä¸Šæœˆçš„ 51.4 å‡è‡³ 51.7ï¼Œåˆ› 2022 å¹´ 6 æœˆä»¥æ¥æ–°é«˜ï¼Œä¸ºçº¦ä¸¤å¹´æ¥æœ€å¿«ï¼Œè¶…è¿‡åˆ†æå¸ˆé¢„æµ‹çš„ 51.5ï¼Œä»è€Œæå‡äº†ç¬¬äºŒå­£åº¦çš„å‰æ™¯...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohuq2byzo/">
    
    
    
    
    
      
    
    ğŸ”»5 æœˆä»½ï¼Œè´¢æ–°åˆ¶é€ ä¸šé‡‡è´­ç»ç†äººæŒ‡æ•°ä»ä¸Šæœˆçš„ 51.4 å‡è‡³ 51.7ï¼Œåˆ› 2022 å¹´ 6 æœˆä»¥æ¥æ–°é«˜ï¼Œä¸ºçº¦ä¸¤å¹´æ¥æœ€å¿«ï¼Œè¶…è¿‡åˆ†æå¸ˆé¢„æµ‹çš„ 51.5ï¼Œä»è€Œæå‡äº†ç¬¬äºŒå­£åº¦çš„å‰æ™¯ã€‚<!-- raw HTML omitted -->ğŸ”»â€œä½†æ˜¯â€ï¼Œè·¯é€ç¤¾è¯´ï¼Œâ€œä½†å…¨çƒé£é™©åŠ å¤§â€ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhusOunQO">ğŸ”»5æœˆç¾å›½åŠå…¶ç‹—è…¿åœ¨ä¸œäºšä¾¦å¯Ÿé£è¡Œçš„ ADB-S é›·è¾¾è½¨è¿¹æƒ…å†µã€‚ğŸ”»via vk/aboutplane [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohusounqo/">
    
    
    
    
    
      
    
    ğŸ”»5æœˆç¾å›½åŠå…¶ç‹—è…¿åœ¨ä¸œäºšä¾¦å¯Ÿé£è¡Œçš„ ADB-S é›·è¾¾è½¨è¿¹æƒ…å†µã€‚<!-- raw HTML omitted -->ğŸ”»via vk/aboutplane <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhuWaqxmh">ğŸ”»ä»¥å†›å›½é˜²éƒ¨å®˜ç½‘æ’­å‡ºäº†ä»¥å†›å‚è°‹é•¿åœ¨åŒ—æ–¹çš„è®²è¯ï¼šğŸ”¹â€œæˆ‘ä»¬æ­£åœ¨æ¥è¿‘å¿…é¡»åšå‡ºå†³å®šçš„æ—¶åˆ»ï¼Œä»¥è‰²åˆ—å›½é˜²å†›å·²ç»åšå¥½å‡†å¤‡ï¼Œéšæ—¶å¯ä»¥å‡ºå‡»â€”â€”çœŸä¸»å…šæœ€è¿‘å‡ å¤©å¢åŠ äº†å…µ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohuwaqxmh/">
    
    
    
    
    
      
    
    ğŸ”»ä»¥å†›å›½é˜²éƒ¨å®˜ç½‘æ’­å‡ºäº†ä»¥å†›å‚è°‹é•¿åœ¨åŒ—æ–¹çš„è®²è¯ï¼š<!-- raw HTML omitted -->ğŸ”¹â€œæˆ‘ä»¬æ­£åœ¨æ¥è¿‘å¿…é¡»åšå‡ºå†³å®šçš„æ—¶åˆ»ï¼Œä»¥è‰²åˆ—å›½é˜²å†›å·²ç»åšå¥½å‡†å¤‡ï¼Œéšæ—¶å¯ä»¥å‡ºå‡»â€”â€”çœŸä¸»å…šæœ€è¿‘å‡ å¤©å¢åŠ äº†å…µåŠ›ã€‚â€<!-- raw HTML omitted -->ğŸ”»â€œåŠ æ²™å¤ªéš¾äº†ï¼Œè¦ä¸æ¢å¼ å·å­åšåšâ€ï¼Œç„¶åå®ƒä»¬çœŸçš„å°±è¦é€‰çœŸä¸»å…šï¼Ÿ<!-- raw HTML omitted -->ğŸ”»çº³æ–¯é²æ‹‰ï¼šå‘€å“ˆæ¯”æ¯”ï¼Œå“ˆæ¯”æ¯”ï¼ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å·´å‹’æ–¯å¦#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_video_defaul">https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_video_defaul</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhuX1AFcN">ğŸ”»é»å·´å«©å—éƒ¨çœŸä¸»å…šè¿™äº›å¹´æ¥çš„çŠ¶æ€å°±åƒï¼š#å·´å‹’æ–¯å¦# åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohux1afcn/">
    
    
    
    
    
      
    
    ğŸ”»é»å·´å«©å—éƒ¨çœŸä¸»å…šè¿™äº›å¹´æ¥çš„çŠ¶æ€å°±åƒï¼š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å·´å‹’æ–¯å¦#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;div style=&ldquo;clear: &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ohux27P9S">ğŸ”»æœ‰äº›ç½‘å‹å¯èƒ½è¿˜æ²¡æœ‰ç†è§£ä¸ºä»€ä¹ˆè¦é€‰æ‹©â€œç„æ­¦å²©å›½æ——â€è¿›è¡ŒåŸä½åˆ©ç”¨çš„æ·±æ„ã€‚ğŸ”»æ³¨æ„æ–‡ä¸­çš„â€œæ— æ¸©æ§ä¿æŠ¤ã€ç‹¬ç«‹åŠ¨æ€å±•ç¤ºâ€ã€‚ğŸ”»æ„æ€å°±æ˜¯ï¼Œè¿™é¢ç”±è¶…ç»†ç„æ­¦å²©çº¤ç»´...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohux27p9s/">
    
    
    
    
    
      
    
    ğŸ”»æœ‰äº›ç½‘å‹å¯èƒ½è¿˜æ²¡æœ‰ç†è§£ä¸ºä»€ä¹ˆè¦é€‰æ‹©â€œç„æ­¦å²©å›½æ——â€è¿›è¡ŒåŸä½åˆ©ç”¨çš„æ·±æ„ã€‚<!-- raw HTML omitted -->ğŸ”»æ³¨æ„æ–‡ä¸­çš„â€œæ— æ¸©æ§ä¿æŠ¤ã€ç‹¬ç«‹åŠ¨æ€å±•ç¤ºâ€ã€‚<!-- raw HTML omitted -->ğŸ”»æ„æ€å°±æ˜¯ï¼Œè¿™é¢ç”±è¶…ç»†ç„æ­¦å²©çº¤ç»´ç¼–åˆ¶è€Œæˆçš„â€œçŸ³å¤´å›½æ——â€ï¼Œä¼šåœ¨æ— æ¸©æ§ä¿æŠ¤çš„æƒ…å†µä¸‹ï¼Œè¿›è¡Œç‹¬ç«‹å±•ç¤ºï¼Œæ¥å—é«˜ä½æ¸©äº¤å˜ã€é«˜çœŸç©ºåŠå¼ºç´«å¤–è¾å°„ç­‰æç«¯ç¯å¢ƒçš„åŠ¨æ€è€ƒéªŒï¼Œé€šè¿‡æŒç»­è§‚å¯Ÿå›½æ——çš„çŠ¶æ€ï¼Œå¯ä»¥è€ƒéªŒç„æ­¦å²©çº¤ç»´åœ¨æœˆé¢ç¯å¢ƒä¸‹çš„é•¿æœŸè€ä¹…æ€§ã€‚<!-- raw HTML omitted -->ğŸ”»ç„æ­¦å²©çº¤ç»´çš„å¼ºåº¦æ˜¯åŒç­‰ç›´å¾„é’¢çº¤ç»´çš„ä¸¤åˆ°ä¸‰å€ï¼Œè€è…èš€æ€§è¶…è¿‡åˆé‡‘ï¼Œèƒ½æ‰¿å—200-300å¨çš„é‡é‡ï¼Œè¿˜èƒ½è€å—è¶…1000â„ƒçš„é«˜æ¸©å’Œé›¶ä¸‹240â„ƒçš„è¶…ä½æ¸©ï¼Œç”¨ç„æ­¦å²©çº¤ç»´åˆ¶æˆé˜²æŠ¤æœï¼Œèƒ½å¤Ÿè€æ¸©éš”çƒ­æŠ—è¾å°„ï¼Œå®ƒè¿˜èƒ½ä»£æ›¿é’¢ç­‹åŠæ–œæ‹‰æ¡¥ï¼Œ200å¹´ä¸ç”¨ç»´ä¿®ï¼Œåœ¨æ²¹æ¼†ä¸­æ·»åŠ ç„æ­¦å²©ææ–™å¯æå‡é‡é˜²è…ä½œç”¨ï¼Œå»¶é•¿ææ–™ä½¿ç”¨å¯¿å‘½ã€‚<!-- raw HTML omitted -->ğŸ”»è€Œç„æ­¦å²©ä¸æœˆå£¤çš„æˆåˆ†ç›¸ä¼¼ï¼Œè¿™æ„å‘³ç€å¦‚æœçœŸçš„èƒ½ç”¨ï¼Œä»¥åå®Œå…¨å¯ä»¥åœ¨æœˆé¢å–æå»ºé€ â€¦â€¦<!-- raw HTML omitted -->ğŸ”»æ²¡æœ‰ä¸€å…‹è½½è·æ˜¯å¤šä½™çš„ã€‚<!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26">https://m.weibo.cn/search?containerid=231522type%3D1%26</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ohuz6eCZL">ğŸ”»è«è¿ªåˆè¾“äº†ï¼ğŸ”»è¿™æ¬¡æ˜¯è¾“ç»™äº†@JacksonHinkle [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohuz6eczl/">
    
    
    
    
    
      
    
    ğŸ”»è«è¿ªåˆè¾“äº†ï¼<!-- raw HTML omitted -->ğŸ”»è¿™æ¬¡æ˜¯è¾“ç»™äº†<!-- raw HTML omitted -->@JacksonHinkle<!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhuzNpgZI">ğŸ”»å›¾2æ˜¯å›¾1çš„è§£é‡Šã€‚ğŸ”»æ™šå®‰ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohuznpgzi/">
    
    
    
    
    
      
    
    ğŸ”»å›¾2æ˜¯å›¾1çš„è§£é‡Šã€‚<!-- raw HTML omitted -->ğŸ”»æ™šå®‰ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com">https://f.video.weibocdn.com</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ohv6AjZwX">ğŸ”»åœ¨ä»¥è‰²åˆ—å›½é˜²å†›å®˜æ–¹ç½‘ç«™å‘å¸ƒä»¥å†›æ€»å‚è°‹é•¿â€œåŒ—æ–¹ä»¥å†›åšå¥½éšæ—¶å‡ºå‡»å‡†å¤‡â€è§†é¢‘åä¸ä¹…ï¼Œé»å·´å«©â€œçœŸä¸»å…šâ€æ­¦è£…å°±åœ¨å…¶å®˜æ–¹ç½‘ç«™è¿ç»­å‘å¸ƒäº†ä¸¤ä¸ªè§†é¢‘ï¼šğŸ”»ä¸€ä¸ªæ˜¯ä½¿ç”¨...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohv6ajzwx/">
    
    
    
    
    
      
    
    ğŸ”»åœ¨ä»¥è‰²åˆ—å›½é˜²å†›å®˜æ–¹ç½‘ç«™å‘å¸ƒä»¥å†›æ€»å‚è°‹é•¿â€œåŒ—æ–¹ä»¥å†›åšå¥½éšæ—¶å‡ºå‡»å‡†å¤‡â€è§†é¢‘åä¸ä¹…ï¼Œé»å·´å«©â€œçœŸä¸»å…šâ€æ­¦è£…å°±åœ¨å…¶å®˜æ–¹ç½‘ç«™è¿ç»­å‘å¸ƒäº†ä¸¤ä¸ªè§†é¢‘ï¼š<!-- raw HTML omitted -->ğŸ”»ä¸€ä¸ªæ˜¯ä½¿ç”¨â€œä¼Šæœ—é«˜çº§å¯¼å¼¹â€è¢­å‡»ä»¥å†› Barkat Risha å“¨æ‰€ï¼Œå¯¼å¼¹çš„å¯¼å¼•å¤´æ‹åˆ°äº†è¢«å‘½ä¸­çš„ä»¥å†›å£«å…µç‰¹å†™ï¼Œä¸€ä¸ªæ˜¯ä½¿ç”¨æ— äººæœºæ‰“æ‰æˆˆå…°é«˜åœ°æ‰ä¹Œæ‹‰åœ°åŒºçš„ä¸€å…·ä»¥å†›é“ç©¹ï¼Œä¹Ÿæ‹åˆ°äº†æ¯ä¼¤ç»“æœè¯„ä¼°ç”»é¢ã€‚<!-- raw HTML omitted -->ğŸ”»ç®€ç›´å°±å¿«æŠŠâ€œä»¥å†›å¿«åŒ—ä¼å§ï¼Œç®€ç›´ç­‰çš„è¦é•¿è˜‘è‡äº†â€å†™åœ¨å¼¹å¹•ä¸Šäº†ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å·´å‹’æ–¯å¦#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video controls=&ldquo;controls&rdquo; poster=&ldquo;<a href="https://tvax4.sinaimg.cn/orj480/639b1bfbly1hqdtn">https://tvax4.sinaimg.cn/orj480/639b1bfbly1hqdtn</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/Ohpwyu3XE">ä¸é”™ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-ohpwyu3xe/">
    
    
    
    
    
      
    
    ä¸é”™ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhqmbbXKz">ä½ çš„æ–‡å­—æˆ‘å–œæ¬¢ğŸ«°ğŸ»//@åƒšå§¬://@æ™®é€šäººé˜¿æ–‡:è‰//@Yashokuå®µå¤œ://@æ·±å¤œèŒ¶åº§://@é™¢å¨_:ï¼ˆã€‚ - è½¬å‘ @æ—¥è¯­ç¿»è¯‘ç¤¾:&amp;ensp;å‘¨ä¸€ï¼å’–å•¡å› æ³¨å…¥ï¼é ‘å¼µã‚‹ç¤¾ä¼šäººã«è´ˆã‚‹ï¼...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohqmbbxkz/">
    
    
    
    
    
      
    
    ä½ çš„æ–‡å­—æˆ‘å–œæ¬¢ğŸ«°ğŸ»//<!-- raw HTML omitted -->@åƒšå§¬<!-- raw HTML omitted -->://<!-- raw HTML omitted -->@æ™®é€šäººé˜¿æ–‡<!-- raw HTML omitted -->:è‰//<!-- raw HTML omitted -->@Yashokuå®µå¤œ<!-- raw HTML omitted -->://<!-- raw HTML omitted -->@æ·±å¤œèŒ¶åº§<!-- raw HTML omitted -->://<!-- raw HTML omitted -->@é™¢å¨_<!-- raw HTML omitted -->:ï¼ˆã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@æ—¥è¯­ç¿»è¯‘ç¤¾<!-- raw HTML omitted -->:â€‚å‘¨ä¸€ï¼<!-- raw HTML omitted -->å’–å•¡å› æ³¨å…¥ï¼<!-- raw HTML omitted -->é ‘å¼µã‚‹ç¤¾ä¼šäººã«è´ˆã‚‹ï¼ &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/005yYAvcly1hqbyewqjtpj30b40b6771.jpg%22">https://tvax4.sinaimg.cn/large/005yYAvcly1hqbyewqjtpj30b40b6771.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhsrKBETc">æ™•äº†è¿™å¼ æ‹å¾—å¥½ç¾ğŸ¥¹//@è¾‰å­_æ‹“å“¦å“¦å“¦:å¦ˆå‘€è˜­è˜­ - è½¬å‘ @æšMizuki:&amp;ensp;#ã®ãå‹•ç”»# [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohsrkbetc/">
    
    
    
    
    
      
    
    æ™•äº†è¿™å¼ æ‹å¾—å¥½ç¾ğŸ¥¹//<!-- raw HTML omitted -->@è¾‰å­_æ‹“å“¦å“¦å“¦<!-- raw HTML omitted -->:å¦ˆå‘€è˜­è˜­<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@æšMizuki<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->#ã®ãå‹•ç”»#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/Ohst63b77">ä¸æƒ³æ´—ç¢—ä¸æƒ³å†™è®ºæ–‡åªæƒ³æ‰“å‰‘ç½‘ä¸‰å®Œäº†æˆ‘æŸ“ä¸Šå‰‘ç½‘ä¸‰äº†ğŸ˜©</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohst63b77/">
    
    
    
    
    
      
    
    ä¸æƒ³æ´—ç¢—ä¸æƒ³å†™è®ºæ–‡åªæƒ³æ‰“å‰‘ç½‘ä¸‰<!-- raw HTML omitted -->å®Œäº†æˆ‘æŸ“ä¸Šå‰‘ç½‘ä¸‰äº†ğŸ˜©  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhtHbhc7W">å¬å¬é¦–é¡µå¹¿ä¸œäººçš„æƒ¨å«ğŸ‘‚ğŸ» - è½¬å‘ @è¿·æƒ‘è¡Œç‚ºå¤§è³:&amp;ensp;ï¼Ÿï¼Ÿï¼Ÿ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohthbhc7w/">
    
    
    
    
    
      
    
    å¬å¬é¦–é¡µå¹¿ä¸œäººçš„æƒ¨å«ğŸ‘‚ğŸ»<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@è¿·æƒ‘è¡Œç‚ºå¤§è³<!-- raw HTML omitted -->:â€‚ï¼Ÿï¼Ÿï¼Ÿ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhuLUumnN">åƒç»‡å„¿æœ¬äºº - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œéº¦å½“åŠ³ éº¦è¾£é¸¡å—å¹¿å‘Šâ€œä½ æ¨å“ªç§é…±ï¼Ÿâ€â€œæˆ‘åŒæ¨ï¼â€ é¡¶ç­†TENä½¿çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohuluumnn/">
    
    
    
    
    
      
    
    åƒç»‡å„¿æœ¬äºº<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->éº¦å½“åŠ³ éº¦è¾£é¸¡å—å¹¿å‘Š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->â€œä½ æ¨å“ªç§é…±ï¼Ÿâ€â€œæˆ‘åŒæ¨ï¼â€<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a href=&ldquo;<a href="https://video.weibo.com/show?fid=1034:">https://video.weibo.com/show?fid=1034:</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhuZlchSw">//@åˆ‘äº‹èª²ä¹‹è™ç‰§é«˜ç¾å’Œ:è½¬å‘å¾®åš - è½¬å‘ @å¤©æ¶¯æ˜æœˆåˆ€OLå®˜å¾®:&amp;ensp;å¤©æ¶¯æ˜æœˆåˆ€OL [é€èŠ±èŠ±]ä¹è½½æ±Ÿæ¹–è·¯æ¼«æ¼«ï¼Œå½’æ¥ä»æ˜¯å°‘å¹´äººï¼[æ‰“call]ç”±åˆ€åˆ€è”åˆåŒäººä½œè€…ä»¬åˆ›ä½œçš„#...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohuzlchsw/">
    
    
    
    
    
      
    
    //<!-- raw HTML omitted -->@åˆ‘äº‹èª²ä¹‹è™ç‰§é«˜ç¾å’Œ<!-- raw HTML omitted -->:è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@å¤©æ¶¯æ˜æœˆåˆ€OLå®˜å¾®<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_default.png%22">https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_default.png&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhvaPtaHp">å¼€å¿ƒï¼</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohvaptahp/">
    
    
    
    
    
      
    
    å¼€å¿ƒï¼  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OhuP7nujh">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œéº¦å½“åŠ³ éº¦è¾£é¸¡å—å¹¿å‘Šâ€œä½ æ¨å“ªç§é…±ï¼Ÿâ€â€œæˆ‘åŒæ¨ï¼â€ é¡¶ç­†TENä½¿çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-ohup7nujh/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->éº¦å½“åŠ³ éº¦è¾£é¸¡å—å¹¿å‘Š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->â€œä½ æ¨å“ªç§é…±ï¼Ÿâ€â€œæˆ‘åŒæ¨ï¼â€<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a href=&ldquo;<a href="https://video.weibo.com/show?fid=1034:5">https://video.weibo.com/show?fid=1034:5</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/OhpLT1I0S">æ£‹æ‰‹æˆ˜é¹°å·²ç»æ˜¯1å¹´å‰çš„äº‹æƒ…äº†ï¼Ÿï¼Ÿï¼Ÿ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-ohplt1i0s/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æ£‹æ‰‹æˆ˜é¹°<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å·²ç»æ˜¯1å¹´å‰çš„äº‹æƒ…äº†ï¼Ÿï¼Ÿï¼Ÿ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OhudxggKY">ä¹…ä¿å²ç»ªé‡Œéº¦å½“åŠ³ éº¦è¾£é¸¡å—å¹¿å‘Šâ€œä½ æ¨å“ªç§é…±ï¼Ÿâ€â€œæˆ‘åŒæ¨ï¼â€ é¡¶ç­†TENä½¿çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-ohudxggky/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->éº¦å½“åŠ³ éº¦è¾£é¸¡å—å¹¿å‘Š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->â€œä½ æ¨å“ªç§é…±ï¼Ÿâ€â€œæˆ‘åŒæ¨ï¼â€<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/Oht9fz2iY">æŸ¯æŸ¯ä¹ŸåŠ æ²¹æ¯•ä¸š[doge] - è½¬å‘ @æ£‹å£«æŸ¯æ´:&amp;ensp;æƒ³ç»™2024å³å°†å‚åŠ é«˜è€ƒçš„åŒå­¦è®²å‡ å¥ç¥ç¦çš„è¯ğŸ€#é«˜è€ƒåŠ æ²¹##é«˜è€ƒ# æ£‹å£«æŸ¯æ´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-oht9fz2iy/">
    
    
    
    
    
      
    
    æŸ¯æŸ¯ä¹ŸåŠ æ²¹æ¯•ä¸š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@æ£‹å£«æŸ¯æ´<!-- raw HTML omitted -->:â€‚æƒ³ç»™2024å³å°†å‚åŠ é«˜è€ƒçš„åŒå­¦è®²å‡ å¥ç¥ç¦çš„è¯ğŸ€<!-- raw HTML omitted --><!-- raw HTML omitted -->#é«˜è€ƒåŠ æ²¹#<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=2315">https://m.weibo.cn/search?containerid=2315</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OhthZEUkI">æŸ¯æ´#æŸ¯æŸ¯bç«™åŠ¨æ€æ¬è¿# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ohthzeuki/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E6%9F%AF%E6%9F%AFb%E7%AB%99%E5%8A%A8%E6%80%81%E6%90%AC%E8%BF%90%23&amp;amp;extparam=%23%E6%9F%AF%E6%9F%AFb%E7%AB%99%E5%8A%A8%E6%80%81%E6%90%AC%E8%BF%90%23%22">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E6%9F%AF%E6%9F%AFb%E7%AB%99%E5%8A%A8%E6%80%81%E6%90%AC%E8%BF%90%23&amp;amp;extparam=%23%E6%9F%AF%E6%9F%AFb%E7%AB%99%E5%8A%A8%E6%80%81%E6%90%AC%E8%BF%90%23&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/Ohtic6Uor">æŸ¯æ´#æŸ¯æŸ¯æŠ–éŸ³åŠ¨æ€æ¬è¿# ä¸»æ’­ç»ˆäºå¿«è¦å›å½’äº†ï¼ [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ohtic6uor/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E6%9F%AF%E6%9F%AF%E6%8A%96%E9%9F%B3%E5%8A%A8%E6%80%81%E6%90%AC%E8%BF%90%23&amp;amp;extparam=%23%E6%9F%AF%E6%9F%AF%E6%8A%96%E9%9F%B3%E5%8A%A8%E6%80%81%E6%259">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E6%9F%AF%E6%9F%AF%E6%8A%96%E9%9F%B3%E5%8A%A8%E6%80%81%E6%90%AC%E8%BF%90%23&amp;amp;extparam=%23%E6%9F%AF%E6%9F%AF%E6%8A%96%E9%9F%B3%E5%8A%A8%E6%80%81%E6%9</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/651838446/answer/3519760191">é‡å­ä½å›ç­”äº†é—®é¢˜: mambaå’Œtransformerçš„å·®å¼‚æ˜¯ä»€ä¹ˆï¼Ÿæœªæ¥mambaä¼šå–ä»£transformerå—ï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-651838446-answer-3519760191/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701543251">é‡å­ä½å‘è¡¨äº†æ–‡ç« : æ–°æ¶æ„Mambaæ›´æ–°äºŒä»£ï¼ä½œè€…ï¼šåˆ«äº‰äº†ï¼Œå·²å»ºç«‹Transformerå’ŒSSMçš„ç»Ÿä¸€ç†è®ºæ¡†æ¶</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701543251/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701546246">é‡å­ä½å‘è¡¨äº†æ–‡ç« : å¥—å£³ä¸‘é—»è®©æ–¯å¦ç¦AI Labä¸»ä»»æ€’äº†ï¼æŠ„è¢­å›¢é˜Ÿ2äººç”©é”…1äººå¤±è¸ªã€å‰ç§‘ç»å†è¢«æ‰’ï¼Œç½‘å‹ï¼šé‡æ–°è®¤è¯†ä¸­å›½å¼€æºæ¨¡å‹</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701546246/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701582258">é‡å­ä½å‘è¡¨äº†æ–‡ç« : å¤šæ¨¡æ€æ¨¡å‹å­¦ä¼šæ‰“æ‰‘å…‹ï¼šè¡¨ç°è¶…è¶ŠGPT-4vï¼Œå…¨æ–°å¼ºåŒ–å­¦ä¹ æ¡†æ¶æ˜¯å…³é”®</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701582258/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701583523">é‡å­ä½å‘è¡¨äº†æ–‡ç« : 3Bæ¨¡å‹æ–°SOTAï¼å¼€æºAIè®©æ—¥å¸¸è°ƒç”¨ä¸åŒå¤§æ¨¡å‹æ›´ç®€å•</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701583523/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701584055">é‡å­ä½å‘è¡¨äº†æ–‡ç« : ç›´æ’­é¢„å‘Šï½œå¯¹è¯æ±‡æ™ºæ™ºèƒ½ï¼šAI Agentè·ç¦»è½åœ°åº”ç”¨è¿˜æœ‰å¤šè¿œï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-04</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701584055/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38825871/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Prognosis and Treatment Strategies for Atrial Fibrillation in Heart Failure with Mildly Reduced Ejection Fraction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38825871-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: AF affects 43% of patients with HFmrEF and represents an independent predictor of adverse long-term &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38827999/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Intraocular lens calcification in a patient with Ehlers-Danlos syndrome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38827999-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND IMPORTANCE: Patients with systemic connective tissue disease, such as a subtype of Ehlers-Danlos, may present with secondary IOL calcification many years after primary lens insertion. This poses an additional consideration when implanting IOLs in these patients.Good visual acuity can be achieved with IOL &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828880/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Adolescent psychiatric inpatients&#39; perceptions of treatment and seclusion</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828880-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Objectives: A great deal of attention is being directed at the use of seclusion in adolescent inpatient psychiatric units due to its forceful nature and negative impact on inpatients and staff. This mixed methods study aimed to explore and compare the level of satisfaction with the services received and perspectives on seclusion in secluded and non-secluded adolescent inpatients.Methods: This study included 188 participants, across three adolescent inpatient psychiatric units in Australia; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828929/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240603181443&amp;v=2.18.0.post9&#43;e462414">Small-Bowel Intussusception in an Adult</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828929-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240603181443-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828929/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240604181823&amp;v=2.18.0.post9&#43;e462414">Small-Bowel Intussusception in an Adult</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828929-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240604181823-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828933/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240603181443&amp;v=2.18.0.post9&#43;e462414">Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828933-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240603181443-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828933/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240604181823&amp;v=2.18.0.post9&#43;e462414">Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828933-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240604181823-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828934/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240603181443&amp;v=2.18.0.post9&#43;e462414">Malicious Midwives, Fruitful Vines, and Bearded Women - Sex, Gender, and Medical Expertise in the &lt;em&gt;Journal&lt;/em&gt;</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828934-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240603181443-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828934/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240604181823&amp;v=2.18.0.post9&#43;e462414">Malicious Midwives, Fruitful Vines, and Bearded Women - Sex, Gender, and Medical Expertise in the &lt;em&gt;Journal&lt;/em&gt;</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828934-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240604181823-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828945/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240603181443&amp;v=2.18.0.post9&#43;e462414">Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828945-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240603181443-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In this phase 3 trial, crinecerfont was superior to placebo in reducing elevated androstenedione levels in pediatric participants with CAH and was also associated with a decrease in the glucocorticoid dose from supraphysiologic to physiologic levels while androstenedione control was maintained. (Funded by Neurocrine Biosciences; CAHtalyst Pediatric ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828945/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240604181823&amp;v=2.18.0.post9&#43;e462414">Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828945-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240604181823-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In this phase 3 trial, crinecerfont was superior to placebo in reducing elevated androstenedione levels in pediatric participants with CAH and was also associated with a decrease in the glucocorticoid dose from supraphysiologic to physiologic levels while androstenedione control was maintained. (Funded by Neurocrine Biosciences; CAHtalyst Pediatric ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828946/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240603181443&amp;v=2.18.0.post9&#43;e462414">Osimertinib after Chemoradiotherapy in Stage III &lt;em&gt;EGFR&lt;/em&gt;-Mutated NSCLC</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828946-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240603181443-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Treatment with osimertinib resulted in significantly longer progression-free survival than placebo in patients with unresectable stage III EGFR-mutated NSCLC. (Funded by AstraZeneca; LAURA ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828946/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240604181823&amp;v=2.18.0.post9&#43;e462414">Osimertinib after Chemoradiotherapy in Stage III &lt;em&gt;EGFR&lt;/em&gt;-Mutated NSCLC</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828946-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240604181823-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Treatment with osimertinib resulted in significantly longer progression-free survival than placebo in patients with unresectable stage III EGFR-mutated NSCLC. (Funded by AstraZeneca; LAURA ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828951/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240603181443&amp;v=2.18.0.post9&#43;e462414">Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828951-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240603181443-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among lenalidomide-exposed patients with relapsed or refractory myeloma, BPd conferred a significantly greater benefit than PVd with respect to progression-free survival, as well as deeper, more durable responses. Ocular events were common but were controllable by belantamab mafodotin dose modification. (Funded by GSK; DREAMM-8 ClinicalTrials.gov number, NCT04484623; EudraCT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828951/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240604181823&amp;v=2.18.0.post9&#43;e462414">Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828951-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240604181823-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among lenalidomide-exposed patients with relapsed or refractory myeloma, BPd conferred a significantly greater benefit than PVd with respect to progression-free survival, as well as deeper, more durable responses. Ocular events were common but were controllable by belantamab mafodotin dose modification. (Funded by GSK; DREAMM-8 ClinicalTrials.gov number, NCT04484623; EudraCT number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828955/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240603181443&amp;v=2.18.0.post9&#43;e462414">Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828955-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240603181443-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with CAH, the use of crinecerfont resulted in a greater decrease from baseline in the mean daily glucocorticoid dose, including a reduction to the physiologic range, than placebo following evaluation of adrenal androgen levels. (Funded by Neurocrine Biosciences; CAHtalyst ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828955/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240604181823&amp;v=2.18.0.post9&#43;e462414">Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828955-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240604181823-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with CAH, the use of crinecerfont resulted in a greater decrease from baseline in the mean daily glucocorticoid dose, including a reduction to the physiologic range, than placebo following evaluation of adrenal androgen levels. (Funded by Neurocrine Biosciences; CAHtalyst ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828984/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240603181443&amp;v=2.18.0.post9&#43;e462414">Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828984-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240603181443-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38828984/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240604181823&amp;v=2.18.0.post9&#43;e462414">Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38828984-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240604181823-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Among patients with resectable, macroscopic stage III melanoma, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-driven adjuvant therapy resulted in longer event-free survival than surgery followed by adjuvant nivolumab. (Funded by Bristol Myers Squibb and others; NADINA ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38829073/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Azimuthal Angle Correlations of Muons Produced via Heavy-Flavor Decays in 5.02Â TeV Pb&#43;Pb and pp Collisions with the ATLAS Detector</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38829073-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Angular correlations between heavy quarks provide a unique probe of the quark-gluon plasma created in ultrarelativistic heavy-ion collisions. Results are presented of a measurement of the azimuthal angle correlations between muons originating from semileptonic decays of heavy quarks produced in 5.02 TeV Pb+Pb and pp collisions at the LHC. The muons are measured with transverse momenta and pseudorapidities satisfying p_{T}^{Î¼}&gt;4 GeV and |Î·^{Î¼}|&lt;2.4, respectively. The distributions of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38829114/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Quantification of human papillomavirus cell-free DNA from low-volume blood plasma samples by digital PCR</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38829114-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The incidence rate of human papillomavirus-driven oropharyngeal cancer (HPV-OPC) is increasing in countries with high human development index. HPV cell-free DNA (cfDNA) isolated from 3 to 4 mL blood plasma has been successfully used for therapy surveillance. A highly discussed application of HPV-cfDNA is early detection of HPV-OPC. This requires sensitive and specific cfDNA detection as cfDNA levels can be very low. To study the predictive power of pre-diagnostic HPV-cfDNA, archived samples &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38829320/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Better source memory for remembered to-be-forgotten items than for remembered to-be-remembered items</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38829320-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    When participants study items one-by-one and are directed to either remember or forget the respective item directly after its presentation, retention of to-be-forgotten items is regularly worse than of to-be-remembered items. We tested whether this directed forgetting effect which is regularly observed for item memory generalizes to source memory. In three experiments, participants studied items in two different source colors (N = 101) or at two different source locations (N = 64; N = &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38829401/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Implant anchorage: In vivo and in vitro analyses : Clusters for implant anchorage and safety</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38829401-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Aseptic implant loosening is the primary cause of revisions in arthroplasty. Various in vitro and in vivo methods are available for assessing implant fixation and stability. The aim of the Musculoskeletal Biomechanics Research Network (MSB-NET) is to continuously improve or develop these methods. In vitro analyses are often conducted using static and dynamic ISO and ASTM standards, while RSA, DXA, and EBRA analyses are established in vivo methods for evaluating implant fixation. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38829520/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Cardiac biomarkers prior to noncardiac surgery</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38829520-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: Cardiac biomarkers, such as high-sensitivity cardiac troponin (hs-cTn) and brain natriuretic peptide (BNP) or Nâ€‘terminal prohormone of brain natriuretic peptide (NT-proBNP) are measured perioperatively to improve the prognosis and risk prediction. The European Society of Cardiology (ESC), European Society of Anesthesiology and Intensive Care (ESAIC) and the German Society of Anesthesiology and Intensive Care Medicine (DGAI) have recently published guidelines on the use of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38829523/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Thanks to Prof. Dr. Roland Kaufmann : Board and editorial team thank the long-serving editor-in-chief of the journal Die Dermatologie</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38829523-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38829625/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240603181530&amp;v=2.18.0.post9&#43;e462414">Type 1 Myocardial Infarction in Patients With Acute Ischemic Stroke</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38829625-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240603181530-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND RELEVANCE: This study found that in patients with acute ischemic stroke, a dynamic change in hs-cTn values did not identify MI, underscoring that dynamic changes do not identify the underlying pathophysiological mechanism. In exploratory analyses, very high absolute hs-cTn values were associated with a diagnosis of type 1 MI. Further studies are needed how to best identify patients with stroke who should undergo coronary &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38830892/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Factor analysis of lifetime psychopathology and its brain morphometric and genetic correlates in a transdiagnostic sample</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38830892-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    There is a lack of knowledge regarding the relationship between proneness to dimensional psychopathological syndromes and the underlying pathogenesis across major psychiatric disorders, i.e., Major Depressive Disorder (MDD), Bipolar Disorder (BD), Schizoaffective Disorder (SZA), and Schizophrenia (SZ). Lifetime psychopathology was assessed using the OPerational CRITeria (OPCRIT) system in 1,038 patients meeting DSM-IV-TR criteria for MDD, BD, SZ, or SZA. The cohort was split into two samples &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38830959/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">CD8&lt;sup&gt;&#43;&lt;/sup&gt; CD28&lt;sup&gt;-&lt;/sup&gt; regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38830959-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38830985/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">RoPod, a customizable toolkit for non-invasive root imaging, reveals cell type-specific dynamics of plant autophagy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38830985-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Arabidopsis root is a classic model system in plant cell and molecular biology. The sensitivity of plant roots to local environmental perturbation challenges data reproducibility and incentivizes further optimization of imaging and phenotyping tools. Here we present RoPod, an easy-to-use toolkit for low-stress live time-lapse imaging of Arabidopsis roots. RoPod comprises a dedicated protocol for plant cultivation and a customizable 3D-printed vessel with integrated microscopy-grade glass &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38830991/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&amp;fc=20220923065203&amp;ff=20240604181742&amp;v=2.18.0.post9&#43;e462414">Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38830991-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1rkszs2hvz2rhp33oibanfew6vk-lzjjwtd4gwmllk8b-wcceh-fc-20220923065203-ff-20240604181742-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or more lines of prior systemic therapy, but there is &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831038/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">A bright green tag for RNA imaging</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831038-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831047/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Acute ischemic stroke and troponin elevation: update of the Mannheim clinical algorithm</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831047-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Elevated high-sensitivity cardiac troponin (hs-cTn) levels should be expected in about half of all patients with acute ischemic stroke (AIS). Since those patients are at risk of increased morbidity and mortality, often attributable to cardiac causes, an adequate work-up of the underlying etiology is required. This can only be achieved by a team of cardiologists and neurologists. Since underlying causes of hs-cTn elevation in AIS patients are diverse, often atypical or silent in their &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38831208/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240604181902&amp;v=2.18.0.post9&#43;e462414">Universal inverse modeling of point spread functions for SMLM localization and microscope characterization</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38831208-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240604181902-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The point spread function (PSF) of a microscope describes the image of a point emitter. Knowing the accurate PSF model is essential for various imaging tasks, including single-molecule localization, aberration correction and deconvolution. Here we present universal inverse modeling of point spread functions (uiPSF), a toolbox to infer accurate PSF models from microscopy data, using either image stacks of fluorescent beads or directly images of blinking fluorophores, the raw data &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OhfwX2wj3">æ™šé¥­åœ¨æ¹¾åŒºåœ°æ ‡é¤å…Burlingameçš„Kincaid Fishåº†ç¥ä¸€ä¸‹ã€‚ ç¾å›½Â·Burlingame [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-ohfwx2wj3/">
    
    
    
    
    
      
    
    æ™šé¥­åœ¨æ¹¾åŒºåœ°æ ‡é¤å…Burlingameçš„Kincaid Fishåº†ç¥ä¸€ä¸‹ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç¾å›½Â·Burlingame<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OhodLdLMb">ä»Šå¤©ç¬¬ä¸€å¤©ä¸Šç­å……æ»¡äº†å…´å¥‹æ„Ÿã€‚åŸæ¥åœ¨Emeryvilleèƒ½çœ‹åˆ°Bay Bridgeå’ŒSFï¼ˆç½‘é¡µé“¾æ¥ï¼‰ï¼›GileadåŠå…¬æ¥¼å¯ä»¥ä»è¥¿ä¾§çœ‹SM Bridgeã€‚æ–°åŠå…¬å®¤ä¸€åˆ‡éƒ½æ˜¯æ ¹æ®ergoï¼ˆäººä½“åŠ›å­¦ï¼‰...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-ohodldlmb/">
    
    
    
    
    
      
    
    ä»Šå¤©ç¬¬ä¸€å¤©ä¸Šç­å……æ»¡äº†å…´å¥‹æ„Ÿã€‚åŸæ¥åœ¨Emeryvilleèƒ½çœ‹åˆ°Bay Bridgeå’ŒSFï¼ˆ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç½‘é¡µé“¾æ¥<!-- raw HTML omitted --><!-- raw HTML omitted -->ï¼‰ï¼›GileadåŠå…¬æ¥¼å¯ä»¥ä»è¥¿ä¾§çœ‹SM Bridgeã€‚æ–°åŠå…¬å®¤ä¸€åˆ‡éƒ½æ˜¯æ ¹æ®ergoï¼ˆäººä½“åŠ›å­¦ï¼‰è®¾è®¡çš„ã€‚ä»Šå¤©é£Ÿå ‚ç‰¹è‰²åˆé¥­æ˜¯éº»å©†è±†è…ï¼›è€Œå¥èº«æˆ¿é‡Œå¯ä»¥çœ‹ç€æµ·æ¹¾è·‘æ­¥ã€‚Gileadç¦»æˆ‘å®¶åªæœ‰4åˆ†é’Ÿï¼Œä¸­åˆå¯ä»¥å›å®¶ã€‚ä½†æœ€è®©æˆ‘å…´å¥‹çš„æ˜¯åˆ°å¤„éƒ½æ˜¯Biktarvyçš„AIDSæˆ–CROI posterï¼Œæƒ³æƒ³è¿‡å»åå¹´æˆ‘ä¸çŸ¥é“è¯»è¿™ä¸ªè¯æ•°æ®å’Œå†™äº†å¤šå°‘è¯„è®ºã€‚æœŸå¾…æ˜å¤©Crottyçš„æŠ¥å‘Šï¼Œä¸Šæ¬¡å¬ä»–æŠ¥å‘Šè¿˜æ˜¯æˆ‘è¯»PhDçš„æ—¶å€™ã€‚ &lt;a href=&ldquo;<a href="http://weibo.com">http://weibo.com</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1444865141/OhgoVzL70">è“èƒ–å­æ—è¾¹ï¼Œæ˜¯ä¸€ä¸ªé“œé”£çƒ§ä¸“å–åº—ï¼Œä¸çŸ¥é“è¿™ä¸¤å®¶åº—æ˜¯ä¸æ˜¯å•†é‡å¥½çš„ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1444865141-ohgovzl70/">
    
    
    
    
    
      
    
    è“èƒ–å­æ—è¾¹ï¼Œæ˜¯ä¸€ä¸ªé“œé”£çƒ§ä¸“å–åº—ï¼Œä¸çŸ¥é“è¿™ä¸¤å®¶åº—æ˜¯ä¸æ˜¯å•†é‡å¥½çš„ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1444865141/Ohkrrgegi">ç¬¬ä¸€æ¬¡ç¾¡æ…•åˆ«äººæ˜¾ç¤ºçš„IPåœ°å€â€¦â€¦ - è½¬å‘ @å«¦å¨¥å…­å·æœˆçƒæ¢æµ‹å™¨:&amp;ensp;å¤§å®¶å¥½ï¼Œæˆ‘æ˜¯å«¦å¨¥å…­å·ï¼Œç°åœ¨æˆ‘æ­£åœ¨æœˆçƒæŒ–åœŸã€‚</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1444865141-ohkrrgegi/">
    
    
    
    
    
      
    
    ç¬¬ä¸€æ¬¡ç¾¡æ…•åˆ«äººæ˜¾ç¤ºçš„IPåœ°å€â€¦â€¦<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@å«¦å¨¥å…­å·æœˆçƒæ¢æµ‹å™¨<!-- raw HTML omitted -->:â€‚å¤§å®¶å¥½ï¼Œæˆ‘æ˜¯å«¦å¨¥å…­å·ï¼Œç°åœ¨æˆ‘æ­£åœ¨æœˆçƒæŒ–åœŸã€‚ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/Ohfzuw7KY">ã€Šç‹å®‰å¿†æµ™å¤§æ–‡å­¦è¯¾ã€‹å‡ºç‰ˆã€‚ç‹è€å¸ˆç­¾äº†å¾ˆå¤šä¹¦ï¼Œé€ç»™å½“æ—¶æ•´ç†å½•éŸ³çš„MFAåŒå­¦ä»¬ã€‚è¿™äº›åŒå­¦å·²ç»æ¯•ä¸šä¸¤å¹´[å¿ƒ] [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-ohfzuw7ky/">
    
    
    
    
    
      
    
    ã€Šç‹å®‰å¿†æµ™å¤§æ–‡å­¦è¯¾ã€‹å‡ºç‰ˆã€‚ç‹è€å¸ˆç­¾äº†å¾ˆå¤šä¹¦ï¼Œé€ç»™å½“æ—¶æ•´ç†å½•éŸ³çš„MFAåŒå­¦ä»¬ã€‚è¿™äº›åŒå­¦å·²ç»æ¯•ä¸šä¸¤å¹´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/62b0d24fly1hqbx3jfp81j21400u0wk">https://tvax1.sinaimg.cn/large/62b0d24fly1hqbx3jfp81j21400u0wk</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/OhgTR3YXX">å€’æ˜¯çœŸçš„[awsl] - è½¬å‘ @å¤´æ¡æ–°é—»:&amp;ensp;#ä¸­å›½æˆå¹´äººç„¦è™‘ç—‡æ‚£ç—…ç‡å·²è¶…è¿‡æŠ‘éƒç—‡#ã€æ¯”æŠ‘éƒç—‡æ›´é«˜å‘çš„å¿ƒç†ç–¾ç—…ï¼Œæ­£åœ¨ä¾µè¢­ä¸­å›½4000å¤šä¸‡æˆå¹´äººã€‘#ç„¦è™‘ç—‡ä¸æ²»ç–—åæœæœ‰...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-ohgtr3yxx/">
    
    
    
    
    
      
    
    å€’æ˜¯çœŸçš„<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@å¤´æ¡æ–°é—»<!-- raw HTML omitted -->:â€‚&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B8%AD%E5%9B%BD%E6%88%90%E5%B9%B4%E4%BA%BA%E7%84%A6%E8%99%91%E7%97%87%E6%82%A3%E7%97%85%E7%8E%87%E5%B7%B2%E8%B6%85%25E">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B8%AD%E5%9B%BD%E6%88%90%E5%B9%B4%E4%BA%BA%E7%84%A6%E8%99%91%E7%97%87%E6%82%A3%E7%97%85%E7%8E%87%E5%B7%B2%E8%B6%85%E</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/OhikFmqgn">å»ä¹°è”ææ±ï¼Œåº—å‘˜è¯´å¾ˆç”œå“¦ï¼Œæˆ‘è¯´å¥½ï¼Œå¥¹è¯´çœŸçš„å¾ˆç”œå“¦ï¼Œæˆ‘è¯´å¥½çš„ä¸ä¹°äº†ã€‚å¥¹è¯´å¥½[è€å¸ˆå¥½]æ€»è€Œè¨€ä¹‹ç•¥æ‡‚ï¼Œè¿™ç§å¹³å¹³æ·¡æ·¡ã€aiæ— æ³•åšåˆ°çš„æ¯ç­æ„Ÿã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-ohikfmqgn/">
    
    
    
    
    
      
    
    å»ä¹°è”ææ±ï¼Œåº—å‘˜è¯´å¾ˆç”œå“¦ï¼Œæˆ‘è¯´å¥½ï¼Œå¥¹è¯´çœŸçš„å¾ˆç”œå“¦ï¼Œæˆ‘è¯´å¥½çš„ä¸ä¹°äº†ã€‚å¥¹è¯´å¥½<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æ€»è€Œè¨€ä¹‹ç•¥æ‡‚ï¼Œè¿™ç§å¹³å¹³æ·¡æ·¡ã€aiæ— æ³•åšåˆ°çš„æ¯ç­æ„Ÿã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhkNQbEfp">ğŸ”»æœ‰ä¸ªé—®é¢˜å—·ï¼šè¿™å‡ å®¶è¿™ä¹ˆé—ªå´©äº†ï¼ˆæˆ–è€…è¯´æ•…éšœäº†ï¼‰ï¼Œä¸ºä»€ä¹ˆæŒ‡æ•°æ²¡åŠ¨å•Š[å“†å•¦Aæ¢¦åƒæƒŠ]ğŸ”»ä½ ä»¬åå°”è¡—ç©æ¨¡æ‹Ÿç›˜çš„å—ï¼Ÿ#ä¼¯å…‹å¸Œå°”å“ˆæ’’éŸ¦# [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohknqbefp/">
    
    
    
    
    
      
    
    ğŸ”»æœ‰ä¸ªé—®é¢˜å—·ï¼šè¿™å‡ å®¶è¿™ä¹ˆé—ªå´©äº†ï¼ˆæˆ–è€…è¯´æ•…éšœäº†ï¼‰ï¼Œä¸ºä»€ä¹ˆæŒ‡æ•°æ²¡åŠ¨å•Š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ğŸ”»ä½ ä»¬åå°”è¡—ç©æ¨¡æ‹Ÿç›˜çš„å—ï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#ä¼¯å…‹å¸Œå°”å“ˆæ’’éŸ¦#<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/639b1bfbgy1hqck6af31jj21gi0xc1kx.jpg%22">https://tvax3.sinaimg.cn/large/639b1bfbgy1hqck6af31jj21gi0xc1kx.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhkRb4As8">è¿™å®¶æœ‰é“æ„å¤§åˆ©äººéœ‡æ€’èœï¼šå®«ä¿é¸¡ä¸ï½æŠ«è¨ğŸ• - è½¬å‘ @ä¹åƒ:&amp;ensp;æ¾³é—¨ç±³å¤«è€å¸ˆæ¥è“‰ï¼Œç›¸é‚€è§é¢ä¸€å™ï¼Œç•…å¨ƒå…¨ç¨‹å®‰æ’ï¼Œä»–ä»¬åƒäº†åˆé¥­ï¼Œçº¦åˆ°äººæ°‘å…¬å›­é¹¤é¸£èŒ¶ç¤¾ä½“éªŒå››å·...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohkrb4as8/">
    
    
    
    
    
      
    
    è¿™å®¶æœ‰é“æ„å¤§åˆ©äººéœ‡æ€’èœï¼šå®«ä¿é¸¡ä¸ï½æŠ«è¨ğŸ•<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@ä¹åƒ<!-- raw HTML omitted -->:â€‚æ¾³é—¨ç±³å¤«è€å¸ˆæ¥è“‰ï¼Œç›¸é‚€è§é¢ä¸€å™ï¼Œç•…å¨ƒå…¨ç¨‹å®‰æ’ï¼Œä»–ä»¬åƒäº†åˆé¥­ï¼Œçº¦åˆ°äººæ°‘å…¬å›­é¹¤é¸£èŒ¶ç¤¾ä½“éªŒå››å·äººçš„èŒ¶æ–‡åŒ–ã€‚è¿™åœ°æ–¹å·²ç»æˆäº†å¤–åœ°äººæ‰“å¡åœ°ï¼Œäººå±±ä¸æµ·ï¼Œæœ¬åœ°äººéƒ½ä¸å¤ªæ•¢å»äº†ï¼Œæ ¹æœ¬æŠ¢ä¸åˆ°ä½å­ã€‚ä»Šå¤©è¿™å¤©æ°”ï¼Œå–èŒ¶æ‘†é¾™é—¨é˜µè¿˜æ˜¯ç›¸å½“æƒ¬æ„ï¼Œæ™šé¤å°±è¿‘å»è“‰æ§¿èŸï¼Œæ–°åº—ç¯å¢ƒå¥½ï¼Œä¸ä¹…å‰å¤§å®¶éƒ½å»åƒè¿‡ï¼Œè¯·å®¢ä¹Ÿä¸è¸©é›·ã€‚ç±³å¤«æ€•è¾£ï¼Œæˆ‘ä»¬å°±è®©ä»–è§è¯†å·èœå‘³å‹çš„ä¸°å¯Œåº¦ï¼Œå…¶å®å°±ç®—å¤§ç™½é±¼è¿™æ ·çš„é…¸è¾£å’Œå£æ°´é¸¡è¿™æ ·çš„éº»è¾£ï¼Œä»–å®Œå…¨å¯ä»¥æ¥å—ï¼Œå¥½çš„å·èœï¼Œåªä¼šæ˜¯ä»¥è¾£ä¿ƒé¦™ï¼Œè€Œä¸æ˜¯ä¸ºäº†è¾£è€Œè¾£ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/8105f481gy1hqck8oc54qj21">https://tvax4.sinaimg.cn/large/8105f481gy1hqck8oc54qj21</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhkSVweoG">ğŸ”»çœ‹çœ‹å¾®åšå°å°¾å·´</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohksvweog/">
    
    
    
    
    
      
    
    ğŸ”»çœ‹çœ‹å¾®åšå°å°¾å·´  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhkXchYu5">ğŸ”»â€œå½“æŠ¥å‘Šå¸‚åœºçš„ä¸€ä¸¾ä¸€åŠ¨çš„æ˜¯äººå·¥æ™ºèƒ½æ—¶ï¼Œè¿˜æœ‰ä»€ä¹ˆå¯èƒ½å‡ºé”™å‘¢ï¼Ÿâ€ğŸ”»å½­åšè‡ªåŠ¨åŒ–æ¼”ç»™ä½ çœ‹ã€‚#æ•°åªç¾è‚¡ç–‘ä¼¼å‡ºç°è¡Œæƒ…å¼‚å¸¸# [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohkxchyu5/">
    
    
    
    
    
      
    
    ğŸ”»â€œå½“æŠ¥å‘Šå¸‚åœºçš„ä¸€ä¸¾ä¸€åŠ¨çš„æ˜¯äººå·¥æ™ºèƒ½æ—¶ï¼Œè¿˜æœ‰ä»€ä¹ˆå¯èƒ½å‡ºé”™å‘¢ï¼Ÿâ€<!-- raw HTML omitted -->ğŸ”»å½­åšè‡ªåŠ¨åŒ–æ¼”ç»™ä½ çœ‹ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#æ•°åªç¾è‚¡ç–‘ä¼¼å‡ºç°è¡Œæƒ…å¼‚å¸¸#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;b &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhkZqemJW">ğŸ”»æ¥ï¼Œé‡æ¸©ä¸€ä¸‹2008å¹´é›·æ›¼å…„å¼Ÿç ´äº§ã€‚ğŸ”»è¯´ä¸å®šè¿™ç´ ææ²¡å¤šä¹…å°±èƒ½ç”¨å¾—ä¸Šäº†ã€‚#æ•°åªç¾è‚¡ç–‘ä¼¼å‡ºç°è¡Œæƒ…å¼‚å¸¸#</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohkzqemjw/">
    
    
    
    
    
      
    
    ğŸ”»æ¥ï¼Œé‡æ¸©ä¸€ä¸‹2008å¹´é›·æ›¼å…„å¼Ÿç ´äº§ã€‚<!-- raw HTML omitted -->ğŸ”»è¯´ä¸å®šè¿™ç´ ææ²¡å¤šä¹…å°±èƒ½ç”¨å¾—ä¸Šäº†ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#æ•°åªç¾è‚¡ç–‘ä¼¼å‡ºç°è¡Œæƒ…å¼‚å¸¸#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video controls=&ldquo;controls&rdquo; poster=&ldquo;<a href="https://tvax4.sinaimg.cn/orj480/639b1bfbly1hqckzpmun0j20t60jqaax">https://tvax4.sinaimg.cn/orj480/639b1bfbly1hqckzpmun0j20t60jqaax</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ohl3T6YXM">ğŸ”»æ³½è¿æ–¯åŸºç”¨æˆ˜äº‰å¨èƒè²å¾‹å®¾äººï¼šâ€œå¦‚æœä¹Œå…‹å…°å¤±è´¥ï¼Œå¦‚æœä¿„ç½—æ–¯å®Œå…¨å é¢†æˆ‘ä»¬ï¼Œæˆ‘ä»¬å°†åœ¨å…¶ä»–å¤§é™†çœ‹åˆ°è¿™åœºæˆ˜äº‰ã€‚å®ƒå¯èƒ½å°±åœ¨ä½ ä»¬çš„æ–¹å‘ï¼Œåœ¨ä½ ä»¬çš„åœ°åŒºã€‚è¿™æ˜¯ä¸€åœºå¤§...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohl3t6yxm/">
    
    
    
    
    
      
    
    ğŸ”»æ³½è¿æ–¯åŸºç”¨æˆ˜äº‰å¨èƒè²å¾‹å®¾äººï¼šâ€œå¦‚æœä¹Œå…‹å…°å¤±è´¥ï¼Œå¦‚æœä¿„ç½—æ–¯å®Œå…¨å é¢†æˆ‘ä»¬ï¼Œæˆ‘ä»¬å°†åœ¨å…¶ä»–å¤§é™†çœ‹åˆ°è¿™åœºæˆ˜äº‰ã€‚å®ƒå¯èƒ½å°±åœ¨ä½ ä»¬çš„æ–¹å‘ï¼Œåœ¨ä½ ä»¬çš„åœ°åŒºã€‚è¿™æ˜¯ä¸€åœºå¤§æ‚²å‰§ã€‚å—å®³è€…ä¼—å¤šã€‚æˆ‘ä»¬ç»ä¸èƒ½è®©ä¿„ç½—æ–¯è·èƒœã€‚â€<!-- raw HTML omitted -->ğŸ”»å®ƒå¯èƒ½ä¸äº†è§£è²å¾‹å®¾äººã€‚<!-- raw HTML omitted -->ğŸ”»è²å¾‹å®¾äººï¼šâ€œç°åœ¨ï¼Œä¿„å›½äººåœ¨æˆ‘ä»¬çš„æµ·æ»©ä¸Šåˆ°å¤„éƒ½æ˜¯å•Šï¼Ÿâ€<!-- raw HTML omitted -->ğŸ”»via RTVM <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video controls=&ldquo;controls&rdquo;  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ohl423lp9">ğŸ”»é¦–é¡µå…¨æ˜¯å¯¹ç€æœˆçƒå®£ç¤ºâ€œè‡ªå¤ä»¥æ¥â€çš„ã€‚</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohl423lp9/">
    
    
    
    
    
      
    
    ğŸ”»é¦–é¡µå…¨æ˜¯å¯¹ç€æœˆçƒå®£ç¤ºâ€œè‡ªå¤ä»¥æ¥â€çš„ã€‚  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ohl5NzcX9">ğŸ”»ä½ è¿™åˆæœ‰ç‚¹æç¬‘äº†ï¼Œæ‹‰è¿™ä¹ˆä¸€ä¸‹ä»€ä¹ˆæ„æ€ï¼Ÿ#æ•°åªç¾è‚¡ç–‘ä¼¼å‡ºç°è¡Œæƒ…å¼‚å¸¸# [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohl5nzcx9/">
    
    
    
    
    
      
    
    ğŸ”»ä½ è¿™åˆæœ‰ç‚¹æç¬‘äº†ï¼Œæ‹‰è¿™ä¹ˆä¸€ä¸‹ä»€ä¹ˆæ„æ€ï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#æ•°åªç¾è‚¡ç–‘ä¼¼å‡ºç°è¡Œæƒ…å¼‚å¸¸#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ohldw2SAW">ğŸ”»è¿ˆå‘æ·±è“ã€‚ğŸ”»æ™šå®‰ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohldw2saw/">
    
    
    
    
    
      
    
    ğŸ”»è¿ˆå‘æ·±è“ã€‚<!-- raw HTML omitted -->ğŸ”»æ™šå®‰ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OhljhesHF">ï¼Ÿ//@åŒ—æ–—_ç‰è¡¡:ä¸è¦ç¡å•Šï¼Œæ˜å¤©ä¸Šåˆå«¦å¨¥å…­å·è¦ä»æœˆçƒèµ·é£äº†ï½ - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»è¿ˆå‘æ·±è“ã€‚ğŸ”»æ™šå®‰ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ohljheshf/">
    
    
    
    
    
      
    
    ï¼Ÿ//<!-- raw HTML omitted -->@åŒ—æ–—_ç‰è¡¡<!-- raw HTML omitted -->:ä¸è¦ç¡å•Šï¼Œæ˜å¤©ä¸Šåˆå«¦å¨¥å…­å·è¦ä»æœˆçƒèµ·é£äº†ï½<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»è¿ˆå‘æ·±è“ã€‚<!-- raw HTML omitted -->ğŸ”»æ™šå®‰ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/Ohjzk5kiS">æ‹¼å‘½ç´¯ç§¯èµ·æ¥çš„ä¸œè¥¿ç»å¯¹ä¸ä¼šèƒŒå›è‡ªå·±ã€‚å¯¹ä¹ˆï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-ohjzk5kis/">
    
    
    
    
    
      
    
    æ‹¼å‘½ç´¯ç§¯èµ·æ¥çš„ä¸œè¥¿ç»å¯¹ä¸ä¼šèƒŒå›è‡ªå·±ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->å¯¹ä¹ˆï¼Ÿ  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3515092710/Ohh32y5Xy">è›¾çœ‰è±†åˆå«é¹…ç±³è±†ï¼Œæˆ‘è€å®¶å«â€œåˆ€åˆ€â€ã€‚ä»Šå¹´è‡ªå®¶æ’­ç§çš„åˆ€åˆ€ï¼Œå¼€èŠ±ï¼Œç»“äº†å…­ä¸ƒä¸ªè±†èšã€‚æˆ‘è¯´æ˜å¤©å°±å‡ºå‘äº†ï¼Œä»Šå¤©æ‘˜ä¸‹æ¥åƒäº†å§ã€‚å–µå¥¶å¥¶è¯´å¤ªå«©äº†å˜›ï¼Œç­‰æˆ‘ä»¬æ—…æ¸¸å›æ¥å†æ‘˜...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3515092710-ohh32y5xy/">
    
    
    
    
    
      
    
    è›¾çœ‰è±†åˆå«é¹…ç±³è±†ï¼Œæˆ‘è€å®¶å«â€œåˆ€åˆ€â€ã€‚ä»Šå¹´è‡ªå®¶æ’­ç§çš„åˆ€åˆ€ï¼Œå¼€èŠ±ï¼Œç»“äº†å…­ä¸ƒä¸ªè±†èšã€‚æˆ‘è¯´æ˜å¤©å°±å‡ºå‘äº†ï¼Œä»Šå¤©æ‘˜ä¸‹æ¥åƒäº†å§ã€‚å–µå¥¶å¥¶è¯´å¤ªå«©äº†å˜›ï¼Œç­‰æˆ‘ä»¬æ—…æ¸¸å›æ¥å†æ‘˜ï¼Ÿæˆ‘è¯´å‘µå‘µï¼Œç­‰æˆ‘ä»¬æ—…æ¸¸å›æ¥ï¼Œè±†èšå¯èƒ½é•¿å¾—æ¯”ä½ éƒ½è¿˜è€äº†ã€‚å–µå¥¶å¥¶æ·¡ç„¶ä¸€ç¬‘ï¼Œå¦‚æœä¸¤ä¸‰å¹´å‰æˆ‘è¿™æ ·è¯´ï¼Œå¥¹ä¼šæ¨ªçœ‰æ€’ç›®è·Ÿæˆ‘æ¯›èµ·ï¼šä½ æœ‰å¥½å¹´è½»å˜›ï¼ç°åœ¨ä¹˜å…¬äº¤åˆ·è€å¹´å¡ï¼Œå¿ƒæ€ä¹Ÿæ…¢æ…¢å¹³å’Œäº†ã€‚å¥¹è¯´æ‰å…­ä¸ƒä¸ªè±†èšï¼Œä¸å¤Ÿä¸€ç›˜èœï¼Œæˆ‘è¯´æˆ‘ä¸æ™“å¾—å»æ¹–å¤¹æ»©ä¹°ï¼Ÿæ¹–å¤¹æ»©è”¬èœä¸€æ¡è¡—çš„åˆ€åˆ€å«â€œé¹…ç±³è±†â€ï¼Œä»·æ ¼ä¸è²ï¼Œ5å…ƒ/æ–¤ã€‚ä¹°äº†åŠæ–¤å¤šï¼Œä¸è‡ªå·±ç§çš„åˆ€åˆ€ä¸€èµ·ï¼Œç»„åˆæˆä¸€ç›˜èœã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3515092710/OhjtGmjAZ">ç¬¬ä¸€æ¬¡ä¹˜åQatar Airwaysçš„èˆªç­ï¼Œèµ·é£å‰24-36å°æ—¶ï¼Œå¯ä»¥ç½‘ä¸Šå€¼æœºï¼Œä½†æˆ‘ä»åˆå2ï¼š00ç­‰åˆ°ç°åœ¨ï¼Œè¿˜æ²¡å¼€å§‹ã€‚æ®è¯´Qatar Airways æ˜¯å›½é™…ä¸€æµèˆªç©ºå…¬å¸ï¼Œä½†ç½‘ä¸Šå€¼æœºæ—¶é—´...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3515092710-ohjtgmjaz/">
    
    
    
    
    
      
    
    ç¬¬ä¸€æ¬¡ä¹˜åQatar Airwaysçš„èˆªç­ï¼Œèµ·é£å‰24-36å°æ—¶ï¼Œå¯ä»¥ç½‘ä¸Šå€¼æœºï¼Œä½†æˆ‘ä»åˆå2ï¼š00ç­‰åˆ°ç°åœ¨ï¼Œè¿˜æ²¡å¼€å§‹ã€‚æ®è¯´Qatar Airways æ˜¯å›½é™…ä¸€æµèˆªç©ºå…¬å¸ï¼Œä½†ç½‘ä¸Šå€¼æœºæ—¶é—´å’‹ä¸ªè¿™ä¹ˆæŠ˜ç£¨äººå‘¢ï¼Ÿ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/OhfS9AtRe">å®Œç¾[æ€’] [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-ohfs9atre/">
    
    
    
    
    
      
    
    å®Œç¾<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/OhgLv9CAl">åƒä¿©ä¸å¤ªä¼šä¸‹æ£‹çš„äººåœ¨ä¸‹ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-ohglv9cal/">
    
    
    
    
    
      
    
    åƒä¿©ä¸å¤ªä¼šä¸‹æ£‹çš„äººåœ¨ä¸‹ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/OhhTyAObN">æŸ¯æ´è¿™æ£‹ä¹Ÿèƒ½è¾“æ˜¯å§</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-ohhtyaobn/">
    
    
    
    
    
      
    
    æŸ¯æ´è¿™æ£‹ä¹Ÿèƒ½è¾“æ˜¯å§  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhiK1qMWe">IMQR//@åºŸè¯å·¨å¤šR:IMSB//@ç–¯ç‹‚æ€ªå«é¹¦:PFMN//@æœ€å¼±ç•ªé•¿æ–©çœŸè±ª:æˆ‘æ˜¯INCEL//@è¥¿æœ¨é‡ç†Š-Mk2:æˆ‘æ˜¯ICBM//@æŸšå­_YUZU:æˆ‘æ˜¯YUZU//@ä¼˜å®¶å°èŠ±èŒ¶:æˆ‘æ˜¯BABY[çˆ±ä½ ]//@Monaå¥åº·...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohik1qmwe/">
    
    
    
    
    
      
    
    IMQR//<!-- raw HTML omitted -->@åºŸè¯å·¨å¤šR<!-- raw HTML omitted -->:IMSB//<!-- raw HTML omitted -->@ç–¯ç‹‚æ€ªå«é¹¦<!-- raw HTML omitted -->:PFMN//<!-- raw HTML omitted -->@æœ€å¼±ç•ªé•¿æ–©çœŸè±ª<!-- raw HTML omitted -->:æˆ‘æ˜¯INCEL//<!-- raw HTML omitted -->@è¥¿æœ¨é‡ç†Š-Mk2<!-- raw HTML omitted -->:æˆ‘æ˜¯ICBM//<!-- raw HTML omitted -->@æŸšå­_YUZU<!-- raw HTML omitted -->:æˆ‘æ˜¯YUZU//<!-- raw HTML omitted -->@ä¼˜å®¶å°èŠ±èŒ¶<!-- raw HTML omitted -->:æˆ‘æ˜¯BABY&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhizGkq1A">è½¬å‘å¾®åš - è½¬å‘ @Amerenka:&amp;ensp;å²©æœ¬è²åŠ #å²©æœ¬è²åŠ # æˆ‘æ˜¯ä¹ƒæœ¨å‚46çš„å²©æœ¬è²åŠ  ç¬¬ä¸€æ¬¡å‡ºæ¼”è¶…ä¹ƒæœ¨å‚starè¯ç”Ÿ ç¬¬ä¸€æ¬¡å•ç‹¬å”±æ­Œååˆ†ç´§å¼  æˆ‘è¦æ¼”å”±çš„æ˜¯ã‚ãŸã‚‰ã‚ˆçš„äº¤å·®...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohizgkq1a/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@Amerenka<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å²©æœ¬è²åŠ <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhjeQD1TQ">ä»¬ç´«ç´«çš„æ­Œç´«å‘³å„¿çœŸé‡ï¼ˆ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohjeqd1tq/">
    
    
    
    
    
      
    
    ä»¬ç´«ç´«çš„æ­Œç´«å‘³å„¿çœŸé‡ï¼ˆ  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhjiunoCC">å‹¾å…«æ•£çƒ­å™¨ä¸å¦‚å°é£æ‰‡å¥½ä½¿ [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohjiunocc/">
    
    
    
    
    
      
    
    å‹¾å…«æ•£çƒ­å™¨ä¸å¦‚å°é£æ‰‡å¥½ä½¿ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhjOQ4T5I">å•Šï¼Ÿ//@å±±ä¸‹æœˆå¤ªéƒ:ï¼Ÿ//@å›è½¬ä¸å¤©ä½¿:ï¼Ÿï¼Ÿï¼Ÿï¼Ÿï¼Ÿï¼Ÿè°å’Œè°ï¼Ÿï¼Ÿ - è½¬å‘ @å¥³å›¢æ‹‰å¨˜å¤§é¥­åº—:&amp;ensp;éŸ©å¨±æ‹‰å¨˜ã€40095ã€‘å§œæµ·ç²¼Ã—æ—©å·åœ£æ¥ã€Šå¦‚æœæˆ‘æŠ“ä¸ä½ã€‹ [å›¾ç‰‡][å›¾ç‰‡][...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohjoq4t5i/">
    
    
    
    
    
      
    
    å•Šï¼Ÿ//<!-- raw HTML omitted -->@å±±ä¸‹æœˆå¤ªéƒ<!-- raw HTML omitted -->:ï¼Ÿ//<!-- raw HTML omitted -->@å›è½¬ä¸å¤©ä½¿<!-- raw HTML omitted -->:ï¼Ÿï¼Ÿï¼Ÿï¼Ÿï¼Ÿï¼Ÿè°å’Œè°ï¼Ÿï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@å¥³å›¢æ‹‰å¨˜å¤§é¥­åº—<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_default.png">https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_default.png</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhkmwpUNJ">éº¦ï¼ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohkmwpunj/">
    
    
    
    
    
      
    
    éº¦ï¼ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhlIkkMCy">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.06.03 13:50ã€Œå“¦å¼å¼ã€æ—©ä¸Šå¥½ã€œå¸Œæœ›ä»Šå¤©ä¹Ÿæ˜¯ç¾å¥½çš„ä¸€å¤©â€¦ï¼å¦‚ä½•è¿ç”¨æ—¶é—´ã€‚æˆ‘è®¤ä¸ºæœ‰æ—¶å€™é€‚...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohlikkmcy/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/se">https://m.weibo.cn/se</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OhlInjbVY">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.06.03 21:06ã€Œå‘œå‘¼å‘¼ã€ä¹…ä¿å²ç»ªé‡Œè™½ç„¶æœ‰ç‚¹æš—ï¼Œä½†å¶å°”å‘å‘ä¹Ÿå¯ä»¥å§ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohlinjbvy/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%25">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/Ohm44q8WA">æ™•äº† - è½¬å‘ @åƒè‘‰é±¿é±¼:&amp;ensp;ğŸµã‚ãŸã‚‰ã‚ˆã€Œäº¤å·®ç‚¹ã€ğŸ¤ å²©æœ¬è“®åŠ  åƒè‘‰é±¿é±¼çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohm44q8wa/">
    
    
    
    
    
      
    
    æ™•äº†<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åƒè‘‰é±¿é±¼<!-- raw HTML omitted -->:â€‚ğŸµã‚ãŸã‚‰ã‚ˆã€Œäº¤å·®ç‚¹ã€<!-- raw HTML omitted -->ğŸ¤ å²©æœ¬è“®åŠ  <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åƒè‘‰é±¿é±¼çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video controls=&ldquo;controls&rdquo; poster=&ldquo;<a href="https://tvax1.sinaimg.cn/orj480/e1c2f1e1gy1hqcp5pgcogj21hc0u0kjl.jp">https://tvax1.sinaimg.cn/orj480/e1c2f1e1gy1hqcp5pgcogj21hc0u0kjl.jp</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/Ohm5L1tbl">9å‘½â€”â€”è²ç³–çš„é¼»éŸ³ï¼Œè°æ‡‚ğŸš¬</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ohm5l1tbl/">
    
    
    
    
    
      
    
    9å‘½â€”â€”è²ç³–çš„é¼»éŸ³ï¼Œè°æ‡‚ğŸš¬  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OhirNrYom">è½‰ç™¼å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#shiorigram# .å¦ç‡ä¸€ç‚¹ä¸ä¹ŸæŒºå¥½çš„å‘€5æœˆã€‚å¦ç‡ä¸€ç‚¹ä¸ä¹ŸæŒºæ£’çš„å—6æœˆã€‚ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-ohirnryom/">
    
    
    
    
    
      
    
    è½‰ç™¼å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;amp;extparam=%25">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23&amp;amp;extparam=%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/OhkRmjjxQ">é‡ç‹ï¼Œæ¢­å“ˆå°ç”³ç ´äº§å¹½ç„ï¼Œå…¨æœç¬¬ä¸€[äºŒå“ˆ] [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-ohkrmjjxq/">
    
    
    
    
    
      
    
    é‡ç‹ï¼Œæ¢­å“ˆå°ç”³ç ´äº§<!-- raw HTML omitted -->å¹½ç„ï¼Œå…¨æœç¬¬ä¸€<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Ohl494oI4">å‘å¸ƒäº†å¤´æ¡æ–‡ç« ï¼šã€Šå¹³å¡šé“åœºâ€”â€”èµµæ²»å‹‹ã€Šæˆ‘çš„å±¥å†ä¹¦ã€‹ï¼ˆ8ï¼‰ã€‹ #å›´æ£‹# å›´æ£‹ å¹³å¡šé“åœºâ€”â€”èµµæ²»å‹‹ã€Šæˆ‘çš„å±¥å†ä¹¦ã€‹ï¼ˆ8ï¼‰ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-ohl494oi4/">
    
    
    
    
    
      
    
    å‘å¸ƒäº†å¤´æ¡æ–‡ç« ï¼šã€Šå¹³å¡šé“åœºâ€”â€”èµµæ²»å‹‹ã€Šæˆ‘çš„å±¥å†ä¹¦ã€‹ï¼ˆ8ï¼‰ã€‹ <!-- raw HTML omitted --><!-- raw HTML omitted -->#å›´æ£‹#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å›´æ£‹<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OhlvPrhmT">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.06.03 21:06ã€Œå‘œå‘¼å‘¼ã€ä¹…ä¿å²ç»ªé‡Œè™½ç„¶æœ‰ç‚¹æš—ï¼Œä½†å¶å°”å‘å‘ä¹Ÿå¯ä»¥å§ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-ohlvprhmt/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/Ohlvt8PN1">ä¹…ä¿å²ç»ªé‡Œ#ä¹…ä¿å²ç»ªé‡Œæ‰‹æœºåš# 2024.06.03 13:50ã€Œå“¦å¼å¼ã€æ—©ä¸Šå¥½ã€œå¸Œæœ›ä»Šå¤©ä¹Ÿæ˜¯ç¾å¥½çš„ä¸€å¤©â€¦ï¼å¦‚ä½•è¿ç”¨æ—¶é—´ã€‚æˆ‘è®¤ä¸ºæœ‰æ—¶å€™é€‚åˆå¯†é›†åœ°å·¥ä½œä¹Ÿæœ‰æ—¶å€™é€‚åˆä¼‘æ¯ã€‚çŸ¥...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-ohlvt8pn1/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OhhaWob6n">æŸ¯æ´#2024ä¹å±…ä¹æ¯ä¸­å›½å›´æ£‹ç”²çº§è”èµ›#VXå·æ­£åœ¨ç›´æ’­[666] [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ohhawob6n/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%232024%E4%B9%90%E5%B1%85%E4%B9%90%E6%9D%AF%E4%B8%AD%E5%9B%BD%E5%9B%B4%E6%A3%8B%E7%94%B2%E7%BA%A7%E8%81%94%E8%B5%9B%23&amp;amp;extparam=%232024%E4%B9%90%E5%B1%258">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%232024%E4%B9%90%E5%B1%85%E4%B9%90%E6%9D%AF%E4%B8%AD%E5%9B%BD%E5%9B%B4%E6%A3%8B%E7%94%B2%E7%BA%A7%E8%81%94%E8%B5%9B%23&amp;amp;extparam=%232024%E4%B9%90%E5%B1%8</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/Ohi6FoacV">æŸ¯æ´#2024ä¹å±…ä¹æ¯ä¸­å›½å›´æ£‹ç”²çº§è”èµ›##èµ›æœå‘å¸ƒ# 2024ä¹å±…ä¹æ¯ä¸­å›½å›´æ£‹ç”²çº§è”èµ›å¸¸è§„èµ›ç¬¬ä¸‰è½®ï¼ŒæŸ¯æ´ä¹æ®µæ‰§é»‘228æ‰‹ä¸­ç›˜è´Ÿè–›å† åå…­æ®µã€‚ ä½œæ­»ç¬¬ä¸€åäº†å±äºã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ohi6foacv/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%232024%E4%B9%90%E5%B1%85%E4%B9%90%E6%9D%AF%E4%B8%AD%E5%9B%BD%E5%9B%B4%E6%A3%8B%E7%94%B2%E7%BA%A7%E8%81%94%E8%B5%9B%23&amp;amp;extparam=%23">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%232024%E4%B9%90%E5%B1%85%E4%B9%90%E6%9D%AF%E4%B8%AD%E5%9B%BD%E5%9B%B4%E6%A3%8B%E7%94%B2%E7%BA%A7%E8%81%94%E8%B5%9B%23&amp;amp;extparam=%23</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OhiGAFpLU">æŸ¯æ´æ—¶è¶Šèƒœå¤çµç›Šï¼ŒæŸ¯æ´è´Ÿè–›å† åï¼Œé™¶æ¬£ç„¶èƒœåˆ˜å…†å“²ï¼Œæœ´å»·æ¡“èƒœé™ˆè€€çƒ¨ã€‚æ·±åœ³é¾™åé˜Ÿ3:1å¼€å°å¥•æ•™é˜Ÿ - è½¬å‘ @æŸ¯æ´ä¹æ®µæ–°é—»æ¬è¿å·:&amp;ensp;æŸ¯æ´#2024ä¹å±…ä¹æ¯ä¸­å›½å›´æ£‹ç”²çº§...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ohigafplu/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted -->æ—¶è¶Šèƒœå¤çµç›Šï¼ŒæŸ¯æ´è´Ÿè–›å† åï¼Œé™¶æ¬£ç„¶èƒœåˆ˜å…†å“²ï¼Œæœ´å»·æ¡“èƒœé™ˆè€€çƒ¨ã€‚æ·±åœ³é¾™åé˜Ÿ3:1å¼€å°å¥•æ•™é˜Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@æŸ¯æ´ä¹æ®µæ–°é—»æ¬è¿å·<!-- raw HTML omitted -->:â€‚&lt;a href=&ldquo;<a href="https://m.weibo.cn/p/index?extparam=%E6%9F%AF%E6%B4%81">https://m.weibo.cn/p/index?extparam=%E6%9F%AF%E6%B4%81</a>&amp; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OhkfBr4mn">æŸ¯æ´#å…­æœˆèµ›ç¨‹#æš‘æ°”æ¸æ·±ï¼Œå›´ç”²ä¹Ÿæ¸å…¥é«˜æ½®ï¼Œæœ¬æœˆå°†å±•å¼€å››è½®æ¿€çƒˆçš„è§’é€ã€‚æœˆä¸­åˆ™æ˜¯ä¼ ç»Ÿèµ›äº‹ï¼ŒæŸ¯æ´ä¹æ®µå±¡æˆ˜å±¡è´¥å±¡è´¥å±¡æˆ˜çš„ï¼Œçƒ‚æŸ¯å›½å†…èµ›ã€‚å›´ç”²æ–°èµ›åˆ¶ä¸‹çš„é¾™åå°†å–å¾—æ€...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ohkfbr4mn/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/346720235/answer/3043498669">ç‹è¯—ç¿”èµåŒäº†å›ç­”: å›½å†…çš„å­¦æœ¯æ°›å›´åˆ°åº•æ€ä¹ˆæ ·ï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-346720235-answer-3043498669/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/657677178/answer/3518397392">å¼ æ•¬ä¿¡å›ç­”äº†é—®é¢˜: ä¸ºä»€ä¹ˆåä¸ºæ‰‹æœºå¦‚æ­¤é’Ÿçˆ±éªé¾™680ï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-657677178-answer-3518397392/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/657971226/answer/3518797946">é‡å­ä½å›ç­”äº†é—®é¢˜: å¦‚ä½•çœ‹å¾…æ–¯å¦ç¦ AI å›¢é˜Ÿè¢«æ›æŠ„è¢­ä¸­å›½é¢å£å¼€æºæ¨¡å‹ï¼Ÿå¼€æºå¦‚ä½•ç»´æŠ¤æƒç›Šï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-657971226-answer-3518797946/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701317251">é‡å­ä½å‘è¡¨äº†æ–‡ç« : OpenAIæŠŠGPT-4åŸå§‹ç‰ˆç»™äº†ä»–ä»¬ï¼šç ”ç©¶ä¸å¾®è°ƒåªé æç¤ºè¯èƒ½èµ°å¤šè¿œ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701317251/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701337413">é‡å­ä½å‘è¡¨äº†æ–‡ç« : ä¸­ç§‘é™¢è‡ªåŠ¨åŒ–æ‰€ç ”å‘è„‰å†²åŠ¨æ€è®¡ç®—çš„æ¯«ç“¦çº§è¶…ä½åŠŸè€—å¼‚æ­¥æ„Ÿç®—ä¸€ä½“ç±»è„‘èŠ¯ç‰‡</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701337413/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701345702">é‡å­ä½å‘è¡¨äº†æ–‡ç« : æ–¯å¦ç¦å›¢é˜Ÿè¢«æ›æŠ„è¢­æ¸…åç³»å¤§æ¨¡å‹ï¼Œå·²åˆ åº“è·‘è·¯</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701345702/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701349528">é‡å­ä½å‘è¡¨äº†æ–‡ç« : è‹±ä¼Ÿè¾¾æ–°ç ”ç©¶ï¼šä¸Šä¸‹æ–‡é•¿åº¦è™šæ ‡ä¸¥é‡ï¼Œ32Kæ€§èƒ½åˆæ ¼çš„éƒ½ä¸å¤š</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701349528/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701356541">é‡å­ä½å‘è¡¨äº†æ–‡ç« : ICML2024é«˜åˆ†ï¼é­”æ”¹æ³¨æ„åŠ›ï¼Œè®©å°æ¨¡å‹èƒ½æ‰“ä¸¤å€å¤§çš„æ¨¡å‹</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701356541/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/701445346">é‡å­ä½å‘è¡¨äº†æ–‡ç« : æ˜†ä»‘ä¸‡ç»´å¼€æº2åƒäº¿ç¨€ç–å¤§æ¨¡å‹å¤©å·¥MoEï¼Œå…¨çƒé¦–åˆ›èƒ½ç”¨4090æ¨ç†</a></h1>
  <div class="date-author">
    
    <span class="date">2024-06-03</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-701445346/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

